Starpharma Holdings (ASX:SPL) rose on Wednesday 19 August 2026. Recently, the company disclosed that UBS Group AG and its related bodies corporate had reduced voting power in Starpharma from 7.05% (33,637,924 votes) to 5.83% (27,791,326 votes), with a change date of 14 August. An institution trimming is not a catalyst for a rally.

What the Company Actually Does

Starpharma's platform is dendrimer chemistry: precisely branched synthetic polymers that carry a drug payload and alter how and where it distributes in the body, branded DEP. Historically the technology was applied to reformulated chemotherapies and to consumer products including VivaGel BV and the VIRALEZE antiviral nasal spray.

The current Investment case is narrower and, on the evidence of this year's announcements, more focused: DEP radiopharmaceuticals. DEP HER2-Lu pairs a dendrimer construct targeting the HER2 receptor with a radioactive isotope — the theranostic approach that has become the most sought-after niche in oncology drug development. The July data package was preclinical and, in the company's own framing, supports entry into Phase 1. That is an important qualifier.

The Bull Case

Radiopharmaceuticals have attracted enormous Capital and repeated large-cap acquisitions globally, and Starpharma has aimed a differentiated delivery chemistry directly at that theme. The July milestone triggering a partner option fee is external validation with cash attached. The raise was fully underwritten and completed, removing near-term funding uncertainty and giving management the Balance Sheet to take DEP HER2-Lu into the clinic. Every director participated, and the stock holds a clear premium to the Offer Price — a sign the raise was absorbed rather than left overhanging the register.

The Risks

DEP HER2-Lu is preclinical. Nothing announced in July involved dosing a human being, and the attrition rate between promising animal data and Phase 1 readouts is unforgiving. The company remains cash-consumptive, and the $32 million raise diluted existing holders by roughly 12%; it will not be the last raise if the program advances. Revenue is milestone-driven and can fall as sharply as it rose — FY2025 revenue fell about 40%. After a 632% twelve months, a great deal of optimism is embedded in the price, and the 79-cent high sits only 8% above Wednesday's level. Finally, that 0.24 relative Volume cuts both ways: a stock that rises 2.1% on thin trade can fall further on the same.

What Happens Next?

The near-term event is the FY2026 full-year result. Stockanalysis.com lists an expected reporting date of 24 August 2026 — an estimate, not a company-confirmed date — which should deliver an audited cash position, a spending profile for the new $32 million and, most importantly, management's timeline for Phase 1 initiation. Watch also whether the partner exercises the option whose fee was triggered in July, and the September-quarter Appendix 4C due in late October.

Bottom Line

Wednesday's 2.1% gain in Starpharma is close to noise: it happened on a quarter of normal volume, with no announcement that day, and the only recent filing showed an institution reducing its stake. The substantive story is July's — positive preclinical DEP HER2-Lu data, a partner option fee, and a fully underwritten $32 million raise at 57 cents that the whole board supported. That has transformed a formerly marginal microcap into a funded radiopharmaceutical developer with a shot on goal. It has also delivered a 632% twelve-month return, which means the easy re-rating is behind it. From here the share price depends on clinical execution, not on days like this one.

  • What was the capital raise?
  • What is DEP HER2-Lu?
  • How much did the stock gain in 12 months?
  • What is the current valuation against FY2025 revenue?
  • What was the partner milestone triggered in July?
  • What other products does Starpharma have?
  • What is the cash runway?

19 August 2026